Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 26:9:e50114.
doi: 10.2196/50114.

Burden of and Trends in Urticaria Globally, Regionally, and Nationally from 1990 to 2019: Systematic Analysis

Xiaoli Liu  1   2 , Yuan Cao  3 , Wenhui Wang  3
Affiliations

Burden of and Trends in Urticaria Globally, Regionally, and Nationally from 1990 to 2019: Systematic Analysis

Xiaoli Liu et al. JMIR Public Health Surveill. .

Abstract

Background: Urticaria presents a significant global health challenge due to its sudden onset and potential for severe allergic reactions. Past data on worldwide prevalence and incidence is inconsistent due to differing study methodologies, regional differences, and evolving diagnostic criteria. Past studies have often provided broad ranges instead of specific figures, underscoring the necessity for a cohesive global perspective to inform public health strategies.

Objective: We aimed to assess the global burden of urticaria using the 2019 Global Burden of Disease (GBD) study data and systematically analyze urticaria prevalence, incidence, and disability-adjusted life years (DALYs) at global, regional, and national levels, thereby informing more effective prevention and treatment strategies.

Methods: We analyzed the global, regional, and national burden of urticaria from 1990 to 2019 using the 2019 GBD study coordinated by the Institute for Health Metrics and Evaluation. Estimations of urticaria prevalence, incidence, and DALYs were derived using DisMod-MR 2.1, a Bayesian meta-regression tool. The Socio-demographic Index (SDI) was used to correlate development status with health outcomes. The GBD's division of the world into 21 regions and 204 countries and territories facilitated a comprehensive assessment. Age-standardized estimated annual percentage changes were generated for urticaria metrics to quantify temporal trends, with age standardization adjusting for potential confounding from age structure.

Results: From 1990 to 2019, the global age-standardized prevalence, incidence, and DALY rates of urticaria showed marginal changes. In 2019, 65.14 million individuals were affected, with a prevalence rate of 841.88 per 100,000 population. The DALY rate was 50.39 per 100,000 population. Compared to 1990, the global age-standardized prevalence, incidence, and DALY rates saw increases of 2.92, 4.84, and 0.31 per 100,000 population, respectively. Women persistently had higher rates than men. At a regional level in 2019, low-middle SDI regions exhibited the highest age-standardized metrics, whereas high SDI regions reported the lowest. Central Europe showed the highest rates, contrasting with Western Europe's lowest rates. Nationally, urticaria prevalence in 2019 varied dramatically, from a low of 27.1 per 100,000 population in Portugal to a high of 92.0 per 100,000 population in Nepal. India reported the most DALYs at 749,495.9, followed by China, Pakistan, and the United States. Agewise data showed higher rates in younger age groups, which diminished with age and then experienced a slight resurgence in the oldest populations. This pattern was pronounced in women and younger populations, with the largest rises seen in those aged less than 40 years and the smallest in those aged more than 70 years.

Conclusions: Urticaria remains a significant global health issue, with considerable variation across regions, countries, and territories. The increased burden among women, the rising burden in younger populations, and the regional differences in disease burden call for tailored interventions and policies to tackle this emerging public health issue.

Keywords: burden of disease; disability-adjusted life years; incidence; prevalence; urticaria.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Global, female, and male age-standardized urticaria DALY rate (A), incidence rate (B), prevalence rate (C), DALY number (D), incident cases (E), and prevalent cases (F) from 1990 to 2019. DALY: disability-adjusted life year.
Figure 2
Figure 2
Urticaria age-standardized DALYs, incidence rate, and prevalence rate for both men and women (A, B, C), women (D, E, F), and men (G, H, I) in different SDI areas from 1990 to 2019. DALY: disability-adjusted life year; SDI: Socio-demographic Index.
Figure 3
Figure 3
Age-standardized DALY rate (A), number of DALYs (B), incidence rate (C), incident cases (D), prevalence rate (E), and prevalent cases (F) for urticaria in 21 disease burden regions from 1990 to 2019. DALY: disability-adjusted life year.
Figure 4
Figure 4
Age-standardized incidence rate (A), age-standardized prevalence rate (B), and age-standardized DALY rate (C) for urticaria per 100,000 population in 2019 in 204 countries and territories. DALY: disability-adjusted life year; NA: not available.
Figure 5
Figure 5
Incident cases (A), prevalent cases (B), and DALY numbers (C) for urticaria in 2019 in 204 countries and territories. DALY: disability-adjusted life year.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zuberbier T, Aberer W, Asero R, Abdul Latiff A H, Baker D, Ballmer-Weber B, Bernstein J A, Bindslev-Jensen C, Brzoza Z, Buense Bedrikow R, Canonica G W, Church M K, Craig T, Danilycheva I V, Dressler C, Ensina L F, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris C H, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Leslie T A, Magerl M, Mathelier-Fusade P, Meshkova R Y, Metz M, Nast A, Nettis E, Oude-Elberink H, Rosumeck S, Saini S S, Sánchez-Borges M, Schmid-Grendelmeier P, Staubach P, Sussman G, Toubi E, Vena G A, Vestergaard C, Wedi B, Werner R N, Zhao Z, Maurer M. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018 Jul;73(7):1393–1414. doi: 10.1111/all.13397. - DOI - PubMed
    1. Kolkhir P, Giménez-Arnau Ana M, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022 Sep 15;8(1):61. doi: 10.1038/s41572-022-00389-z.10.1038/s41572-022-00389-z - DOI - PubMed
    1. Antia C, Baquerizo K, Korman A, Bernstein JA, Alikhan A. Urticaria: A comprehensive review: Epidemiology, diagnosis, and work-up. J Am Acad Dermatol. 2018 Oct;79(4):599–614. doi: 10.1016/j.jaad.2018.01.020.S0190-9622(18)30139-7 - DOI - PubMed
    1. Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein J, Ensina L, Fomina D, Galvàn C A, Godse K, Grattan C, Hide M, Katelaris C, Khoshkhui M, Kocatürk E, Kulthanan K, Medina I, Nasr I, Peter J, Staubach P, Wang L, Weller K, Maurer M. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021 Feb;184(2):226–236. doi: 10.1111/bjd.19561. - DOI - PubMed
    1. Stadler P, Marsela E, Kämmerer Till, Frommherz LH, Clanner-Engelshofen B, French LE, Oppel E, Reinholz M. Impact of allergic reactions and urticaria on mental health and quality of life. Allergol Immunopathol (Madr) 2022;50(2):124–130. doi: 10.15586/aei.v50i2.525. - DOI - PubMed